Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Q1 net income surges to $451m
Teva Pharmaceutical Industries, an Israeli pharmaceutical company, has reported a net income of $451m, or $0.51 diluted earnings per share, for the first quarter of 2009 compared to
Teva Pharmaceutical Industries, an Israeli pharmaceutical company, has reported a net income of $451m, or $0.51 diluted earnings per share, for the first quarter of 2009 compared to
Rexahn Pharmaceuticals, a biopharmaceutical company, has reported preliminary results for its sexual dysfunction drug candidate, Zoraxel, from a Phase IIa clinical study for the treatment of erectile dysfunction.
Indian pharmaceutical company Jubilant Organosys has reported that its subsidiary in the US, Draximage has received FDA approval for the company’s abbreviated new drug application for generic Sestamibi.
Eclipsys, a provider of clinical, revenue cycle and performance management software, has released an influenza A H1N1 Outcomes Toolkit designed to help limit the spread of the H1N1
US-based clinical-stage company Heat Biologics and The University of Miami Miller School of Medicine have reported that the University’s Institutional Review Board or IRB has approved an expansion
Genentech, a biotechnology company, has reported that FDA has granted accelerated approval of Avastin for people with glioblastoma with progressive disease following prior therapy. The new indication for
Instrumentation Laboratory and its parent company Instrumentation Laboratory SpA or IL have reported that the Paris First Level Civil Court has determined that Diagnostica Stago infringed the French
As part of the agreement, AstraZeneca researchers plan to leverage the analysis application, to build biological models, analyze data, and answer biological and chemical questions in their effort
GlaxoSmithKline granted a license to Simcere in 2006 to make products containing zanamivir. Simcere is reportedly the only pharmaceutical company in mainland China that has such a license.
For the first quarter of 2009, net sales decreased 10.7% to $301.5 million from $337.7 million in the first quarter of 2008. James Foster, chairman, president and CEO